ストックスクリーナーアプリを入手
2.03
5.58%
-0.12
アフターアワーズ：
2.04
0.01
+0.49%
Jyong Biotech Ltd (MENS) 最新ニュース
Jyong Biotech Ltd. Ordinary Shares (NASDAQ: MENS) Share Price, MENS Stock News, MENS Share Price & Updates - Kalkine
Jyong Biotech (MENS) Jumps 7.6% to $2.28, Closing in on Resistance at $2.39Throwback Trade - siam.in
A plant-based drug developer will join a two-language online investor event Sept. 6 - Stock Titan
Jyong Biotech Announces Participation in StockFan Virtual Investor Non-Deal Roadshow - GlobeNewswire
Jyong (MENS) Move: Gains 2.88% to Reach $2.14 on the Day; Current Setup: the Session Ends Within the Reported Technical Boundaries on the DayVolume Nodes - vinanet.vn
Jyong Biotech (MENS) Holds Flat at $2.1 as Shares Consolidate Between Key Support and Resistance LevelsLow Beta Factor - vinanet.vn
Jyong Biotech (MENS) Edges Up to $2.03, Holding a Tight Range Between Support and ResistanceDynamic Hedging - dars.gov.et
Jyong Biotech (MENS) Dips 0.98% to $2.03 as Biotech Stock Tests Range-Bound SupportFund Manager Survey - careplusvn.com
Jyong Biotech Highlights Multi-Billion Dollar Global BPH Market Opportunity and Reaffirms Strategic Focus on Global Licensing Partnerships - Macau Business
Jyong Biotech Ltd (MENS) Institutional Confidence - TradingKey
Jyong Biotech Ltd (MENS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Jyong Biotech Ltd (MENS) Income Statement - TradingKey
Jyong Biotech Ltd (MENS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
MENS|Jyong Biotech Ltd|Price:2.360|Chg%:-0.350 - TradingKey
Jyong Biotech Ltd (MENS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Jyong Biotech Ltd (MENS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Jyong Biotech Ltd (MENS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Jyong Biotech Ltd (MENS) Balance Sheet - TradingKey
Jyong Biotech Ltd (MENS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Jyong Biotech pursues global licensing partnerships for BPH drug By Investing.com - Investing.com Nigeria
Jyong Biotech targets $22B global BPH market wi... - Pluang
Jyong Biotech pursues global licensing partnerships for BPH drug - Investing.com
Jyong Biotech Ltd. Reaffirms Global Licensing Strategy for Botanical BPH Drug Candidate Botreso - Quiver Quantitative
Benign prostatic hyperplasia patients projected to reach 150M-156M by 2035 - Stock Titan
Jyong Biotech (MENS) Gains 3.88% as Positive Momentum Targets Key ResistanceVolume Dry Up - careplusvn.com
Jyong Biotech Ltd. (NASDAQ:MENS) Short Interest Down 36.2% in June - MarketBeat
Jyong Biotech (MENS) Dips 1.3% as Stock Approaches Key Support at $2.16High Beta Stocks - careplusvn.com
Jyong Biotech Showcases Botanical Drug Portfolio at BIO 2026 International Convention - Macau Business
Jyong Biotech presents drug candidate at BIO 2026 convention By Investing.com - Investing.com Nigeria
Jyong Biotech presents drug candidate at BIO 2026 convention - Investing.com
Jyong Biotech advances botanical drug Botreso® at BIO 2026, targeting global licensing for BPH treatment. - Pluang
Jyong Biotech (MENS) Retreats Over 5% as Key Support Test LoomsForce Index - dars.gov.et
Price to sales forward of Jyong Biotech Ltd. – NASDAQ:MENS - TradingView
Enterprise value to EBIT forward of Jyong Biotech Ltd. – NASDAQ:MENS - TradingView
Enterprise value to EBITDA forward of Jyong Biotech Ltd. – NASDAQ:MENS - TradingView
Price to book forward of Jyong Biotech Ltd. – NASDAQ:MENS - TradingView
Jyong Biotech Ltd. (MENS) Modest Gain Amidst Tight Trading RangeDefined Outcome ETF - DonanımHaber
Jyong Biotech Ltd (MENS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Number of shareholders of Jyong Biotech Ltd. – NASDAQ:MENS - TradingView
Jyong Biotech Ltd (MENS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Certain Ordinary Shares of Jyong Biotech Ltd. are subject to a Lock-Up Agreement Ending on 16-JUN-2026. - marketscreener.com
JYONG BIOTECH LTD (MENS) Stock Chart - ChartMill
Jyong Biotech CEO Outlines FDA Pathway and Global Strategy in PharmaBoardroom Live Interview - digitalmore.co
Jyong Biotech outlines FDA approval path for botanical drug Botreso® targeting benign prostatic hyperplasia. - Pluang
Jyong Biotech (MENS) Remains Range-Bound as Price Consolidates Near SupportPut Flow Alert - The Legal Advocate
MENSJyong Biotech Ltd Stock Price and Quote - Finviz
Jyong Biotech Ltd. (MENS) Rises 2.36% as Stock Approaches Key ResistanceElliott Wave Count - dars.gov.et
Jyong Biotech Ltd. (MENS) Surges 3.37% as Buyers Defend Key Support LevelTake Profit Levels - The Legal Advocate
Jyong Biotech Ltd. (MENS) Shows Resilience: Uptick from Key Support ZoneImbalance Zone - The Legal Advocate
3.06%
2.55%
大文字化:
|
ボリューム (24 時間):